FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967939076> ?p ?o ?g. }

• W2967939076 endingPage "S7" @default.
• W2967939076 startingPage "S7" @default.
• W2967939076 abstract "Introduction Hypertension remains a prevalent challenge that induces high morbidity and mortality in the general population. It is also known to be an important risk factor for heart failure (HF) incidence. There remains an urgent need for the development of antihypertensive agents with novel mechanisms of action, particularly for resistant hypertension which markedly increases risk for HF. ZD100 (also called MANP) is a novel designer natriuretic peptide that potently activates particulate guanylyl cyclase A receptor (pGC-A) and its second messenger cGMP, is highly resistant to neprilysin degradation and mediates vasodilation with marked natriuresis and diuresis and inhibition of aldosterone, supporting its potential effectiveness for hypertension. The use of ZD100 for hypertension, however, is limited by its delivery method in which its activity to date was only tested with continuous intravenous infusion in short-term acute studies. Subcutaneous (SC) injection of peptide therapeutics has demonstrated impressive safety, greater convenience and lower medical cost. Importantly, the long term effects of ZD100 in experimental hypertension remain unknown. Hypothesis We hypothesize that ZD100 SC administration yields favorable cardiovascular (CV) and renal actions in normal rats and chronically ZD100 reduces blood pressure (BP) in a hypertensive rat model. Methods In normal Sprague Dawley rats, acute SC ZD100 (low: 1.94 mg/kg, high: 3.88 mg/kg, n=5) or vehicle (0.9% saline, n=5) were administered and BP, urine output, urinary sodium excretion, and plasma cGMP, ZD100, and aldosterone were measured. In sodium-deficient-diet induced hypertensive Sprague Dawley rats, daily SC injection for 7 days of ZD100 (3.88mg/kg, n=10) or vehicle (n=9) were performed and CV, renal and neurohumoral parameters were obtained at day 7. Data are presented as absolute changes from baseline values and expressed as Mean±SEM. *p Results Acute SC ZD100 induced potent and dose-dependent BP lowering effects over 360 min compared to vehicle in normal rats (high: -29.0±8.2*, low: -14.8±5.5, veh: -6.3±3.6 mmHg). In parallel, robust diuresis, natriuresis and GMP activation were seen with ZD100. Specifically, diuresis and natriuresis increased 3-5 fold by ZD100 compared to vehicle. We then determined its chronic CV and renal actions in a hypertensive model in rats. ZD100 SC daily for 7 days elevated plasma ZD100 levels and exhibited BP lowering effects compared to vehicle (ZD100: -6.1±4.9*, veh: +10.5±5.7 mmHg), with increased plasma levels of cGMP (ZD100: 112±18*, veh: 33±5 pmol/mL) and a trend for diuretic and natriuretic enhancement and aldosterone suppression. Conclusion Our study thus supports the effectiveness of chronic SC use of ZD100, a novel and best-in-class pGC-A/cGMP peptide activator in experimental hypertension and supporting its clinical development in hypertension." @default.
• W2967939076 created "2019-08-22" @default.
• W2967939076 creator A5014193048 @default.
• W2967939076 creator A5020819058 @default.
• W2967939076 creator A5028644714 @default.
• W2967939076 creator A5064422018 @default.
• W2967939076 creator A5084326396 @default.
• W2967939076 date "2019-08-01" @default.
• W2967939076 modified "2023-10-16" @default.
• W2967939076 title "Acute and Chronic Subcutaneous Administration of ZD100, a Novel pGC-A/cGMP Peptide Activator, Demonstrates Robust Antihypertensive Efficacy in Rodents" @default.
• W2967939076 doi "https://doi.org/10.1016/j.cardfail.2019.07.026" @default.
• W2967939076 hasPublicationYear "2019" @default.
• W2967939076 type Work @default.
• W2967939076 sameAs 2967939076 @default.
• W2967939076 citedByCount "0" @default.
• W2967939076 crossrefType "journal-article" @default.
• W2967939076 hasAuthorship W2967939076A5014193048 @default.
• W2967939076 hasAuthorship W2967939076A5020819058 @default.
• W2967939076 hasAuthorship W2967939076A5028644714 @default.
• W2967939076 hasAuthorship W2967939076A5064422018 @default.
• W2967939076 hasAuthorship W2967939076A5084326396 @default.
• W2967939076 hasBestOaLocation W29679390761 @default.
• W2967939076 hasConcept C126322002 @default.
• W2967939076 hasConcept C170493617 @default.
• W2967939076 hasConcept C17744445 @default.
• W2967939076 hasConcept C199539241 @default.
• W2967939076 hasConcept C2780765947 @default.
• W2967939076 hasConcept C71924100 @default.
• W2967939076 hasConcept C88045685 @default.
• W2967939076 hasConcept C98274493 @default.
• W2967939076 hasConceptScore W2967939076C126322002 @default.
• W2967939076 hasConceptScore W2967939076C170493617 @default.
• W2967939076 hasConceptScore W2967939076C17744445 @default.
• W2967939076 hasConceptScore W2967939076C199539241 @default.
• W2967939076 hasConceptScore W2967939076C2780765947 @default.
• W2967939076 hasConceptScore W2967939076C71924100 @default.
• W2967939076 hasConceptScore W2967939076C88045685 @default.
• W2967939076 hasConceptScore W2967939076C98274493 @default.
• W2967939076 hasIssue "8" @default.
• W2967939076 hasLocation W29679390761 @default.
• W2967939076 hasOpenAccess W2967939076 @default.
• W2967939076 hasPrimaryLocation W29679390761 @default.
• W2967939076 hasRelatedWork W1995515455 @default.
• W2967939076 hasRelatedWork W2062341314 @default.
• W2967939076 hasRelatedWork W2150866608 @default.
• W2967939076 hasRelatedWork W2267959400 @default.
• W2967939076 hasRelatedWork W2748952813 @default.
• W2967939076 hasRelatedWork W2899084033 @default.
• W2967939076 hasRelatedWork W2905320633 @default.
• W2967939076 hasRelatedWork W2950269884 @default.
• W2967939076 hasRelatedWork W3031052312 @default.
• W2967939076 hasRelatedWork W3032375762 @default.
• W2967939076 hasVolume "25" @default.
• W2967939076 isParatext "false" @default.
• W2967939076 isRetracted "false" @default.
• W2967939076 magId "2967939076" @default.
• W2967939076 workType "article" @default.